23:04 , Jul 28, 2017 |  BC Extra  |  Clinical News

Idorsia insomnia candidate headed for Phase III

Idorsia Ltd. (SIX:IDIA) said ACT-541468 led to a significant, dose-dependent reduction in Wake After Sleep Onset (WASO) from baseline on the first two nights of treatment in a pair of Phase II trials to treat...
07:00 , Oct 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Orexin 2 receptor (OX2R; HCRTR2)

Neurology INDICATION: Cataplexy; narcolepsy Cell culture and mouse studies identified an OX2R activator that could help treat cataplexy and narcolepsy. Screening of a small molecule library in a mammalian cell-based assay of OX2R-mediated calcium signaling...
07:00 , Aug 17, 2015 |  BioCentury  |  Product Development

Structure knows best

Although most of Heptares' compounds are against clinically validated targets, and only one currently boasts first-in-class potential, the structure-based drug design company is building a case for its ability to expand targets into new indications,...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Merck sales and marketing update

Merck launched Belsomra suvorexant in the U.S. to treat adults with insomnia. The dual orexin receptor antagonist is available in 5, 10, 15 and 20 mg oral tablets with a wholesale acquisition cost (WAC) of...
08:00 , Feb 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Orexin 1 receptor (HCRTR1; OX1R)

Neurology INDICATION: Panic Rat studies suggest a brain-penetrating OX1R antagonist could help treat stress- and hyperarousal-associated psychiatric disorders such as panic. Previous chemical synthesis and in vitro testing identified an antagonist that selectively bound human...
08:00 , Jan 12, 2015 |  BioCentury  |  Finance

Buyside view XXIII: Milestones galore

Stephen Hansen, Associate Editor and Jennifer Rhodes, Staff Writer   Buyside view XXIII The maturation of the biotech sector over the past few years finds fund managers focusing on a slew of clinical milestones and...
07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Suvorexant regulatory update

FDA approved Belsomra suvorexant from Merck to treat insomnia. The pharma said it plans to launch the dual orexin receptor antagonist in the U.S. by late 2014 or early 2015. The launch is contingent on...
01:34 , Aug 14, 2014 |  BC Extra  |  Top Story

FDA approves Merck's suvorexant

FDA approved Belsomra suvorexant from Merck & Co. Inc. (NYSE:MRK) to treat insomnia. The pharma said it plans to make the dual orexin receptor antagonist available in the U.S. by late 2014 or early 2015....
07:00 , Aug 11, 2014 |  BC Week In Review  |  Clinical News

Suvorexant regulatory update

Merck disclosed in its 2Q14 financial results that FDA assigned a PDUFA date of Aug. 14 for a resubmitted application for once-daily suvorexant to treat insomnia. In July 2013, FDA issued a complete response letter...